Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase.

Baum PD, Sullam PM, Stoddart CA, McCune JM.

AIDS. 2011 Nov 28;25(18):2243-8. doi: 10.1097/QAD.0b013e32834d3cc3.

2.

In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients.

Falcinelli E, Francisci D, Belfiori B, Petito E, Guglielmini G, Malincarne L, Mezzasoma A, Sebastiano M, Conti V, Giannini S, Bonora S, Baldelli F, Gresele P.

Thromb Haemost. 2013 Aug;110(2):349-57. doi: 10.1160/TH12-07-0504. Epub 2013 May 23.

PMID:
23703656
3.

Differentiation of cGMP-dependent and -independent nitric oxide effects on platelet apoptosis and reactive oxygen species production using platelets lacking soluble guanylyl cyclase.

Rukoyatkina N, Walter U, Friebe A, Gambaryan S.

Thromb Haemost. 2011 Nov;106(5):922-33. doi: 10.1160/TH11-05-0319. Epub 2011 Jul 28.

PMID:
21800013
4.

Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats.

Schäfer A, Flierl U, Kobsar A, Eigenthaler M, Ertl G, Bauersachs J.

Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2813-8. Epub 2006 Oct 5.

5.

Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.

Mendes-Silverio CB, Leiria LO, Morganti RP, Anhê GF, Marcondes S, Mónica FZ, De Nucci G, Antunes E.

PLoS One. 2012;7(11):e47223. doi: 10.1371/journal.pone.0047223. Epub 2012 Nov 8.

6.

Abacavir has no prothrombotic effect on platelets in vitro.

Diallo YL, Ollivier V, Joly V, Faille D, Catalano G, Jandrot-Perrus M, Rauch A, Yeni P, Ajzenberg N.

J Antimicrob Chemother. 2016 Dec;71(12):3506-3509. Epub 2016 Aug 11.

PMID:
27516475
7.

Platelet hyperaggregability in high-fat fed rats: a role for intraplatelet reactive-oxygen species production.

Monteiro PF, Morganti RP, Delbin MA, Calixto MC, Lopes-Pires ME, Marcondes S, Zanesco A, Antunes E.

Cardiovasc Diabetol. 2012 Jan 16;11:5. doi: 10.1186/1475-2840-11-5.

8.

Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure.

Schäfer A, Fraccarollo D, Werner L, Bauersachs J.

Pharmacol Res. 2010 Nov;62(5):432-8. doi: 10.1016/j.phrs.2010.06.008. Epub 2010 Jun 22.

PMID:
20600916
9.
10.

Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation.

Zhang G, Xiang B, Dong A, Skoda RC, Daugherty A, Smyth SS, Du X, Li Z.

Blood. 2011 Sep 29;118(13):3670-9. doi: 10.1182/blood-2011-03-341107. Epub 2011 Jul 29.

11.

Stimulatory roles of nitric-oxide synthase 3 and guanylyl cyclase in platelet activation.

Marjanovic JA, Li Z, Stojanovic A, Du X.

J Biol Chem. 2005 Nov 11;280(45):37430-8. Epub 2005 Sep 6.

12.

Nitric oxide-sensitive guanylyl cyclase is the only nitric oxide receptor mediating platelet inhibition.

Dangel O, Mergia E, Karlisch K, Groneberg D, Koesling D, Friebe A.

J Thromb Haemost. 2010 Jun;8(6):1343-52. doi: 10.1111/j.1538-7836.2010.03806.x. Epub 2010 Feb 11.

13.

Antitumor antibiotic streptonigrin and its derivatives as inhibitors of nitric oxide-dependent activation of soluble guanylyl cyclase.

Severina IS, Pyatakova NV, Postnikov AB, Preobrazhenskaya MN, Khropov YV.

Eur J Pharmacol. 2004 Jan 12;483(2-3):127-32.

PMID:
14729099
14.

Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy.

Satchell CS, O'Halloran JA, Cotter AG, Peace AJ, O'Connor EF, Tedesco AF, Feeney ER, Lambert JS, Sheehan GJ, Kenny D, Mallon PW.

J Infect Dis. 2011 Oct 15;204(8):1202-10. doi: 10.1093/infdis/jir509.

PMID:
21917893
15.

Analysis of nitric oxide-sensitive guanylyl cyclase in human platelets before and after aggregation.

Kempfert J, Behrends S.

Platelets. 2003 Nov-Dec;14(7-8):429-35.

PMID:
14713512
16.

Nitric oxide-dependent and independent effects on human platelets treated with peroxynitrite.

Brown AS, Moro MA, Masse JM, Cramer EM, Radomski M, Darley-Usmar V.

Cardiovasc Res. 1998 Nov;40(2):380-8.

PMID:
9893732
17.

[Potentiation of nitric oxide-dependent activation of soluble guanylate cyclase by levomycetin, tetracycline, and oxolin].

Shchegolev AIu, Sidorova TA, Severina IS.

Biomed Khim. 2009 May-Jun;55(3):331-7. Russian.

PMID:
19663005
18.

Soluble guanylyl cyclase is the only enzyme responsible for cyclic guanosine monophosphate synthesis in human platelets.

Gambaryan S, Subramanian H, Rukoyatkina N, Herterich S, Walter U.

Thromb Haemost. 2013 May;109(5):973-5. doi: 10.1160/TH12-12-0916. Epub 2013 Mar 7. No abstract available.

PMID:
23467662
19.

An ex vivo standardized assay to measure human platelet cGMP.

di Villa Bianca Rd, Mitidieri E, Mirone V, Fusco F, Imbimbo C, Cirino G, Sorrentino R.

J Pharmacol Toxicol Methods. 2011 Sep-Oct;64(2):164-7. doi: 10.1016/j.vascn.2011.07.001. Epub 2011 Jul 23.

PMID:
21801844
20.

Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.

Chlopicki S, Olszanecki R, Marcinkiewicz E, Lomnicka M, Motterlini R.

Cardiovasc Res. 2006 Jul 15;71(2):393-401. Epub 2006 Mar 22.

PMID:
16713591

Supplemental Content

Support Center